Narrow search
Showing 1 - 10 of 61
Cover Image
Requirements for benefit assessment in Germany and England: Overview and comparison
Ivandic, Victor - In: Health Economics Review 4 (2014) 12, pp. 1-14
Federal Joint Committee/Institute for Quality and Efficiency in Health Care (G-BA/IQWiG; Germany) and the National Institute … approach taken by NICE seems to be more open and less restrictive as compared with G-BA/IQWiG. Any kind of potentially relevant … sensitivity analyses before making a recommendation regarding reimbursement. By contrast, G-BA/IQWiG bases its assessment and …
Persistent link: https://www.econbiz.de/10011599801
Cover Image
Requirements for benefit assessment in Germany and England : overview and comparison
Ivandic, Victor - In: Health economics review 4 (2014) 12, pp. 1-14
Federal Joint Committee/Institute for Quality and Efficiency in Health Care (G-BA/IQWiG; Germany) and the National Institute … approach taken by NICE seems to be more open and less restrictive as compared with G-BA/IQWiG. Any kind of potentially relevant … sensitivity analyses before making a recommendation regarding reimbursement. By contrast, G-BA/IQWiG bases its assessment and …
Persistent link: https://www.econbiz.de/10010528485
Cover Image
Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland
Lebioda, Andrea; Gasche, David; Dippel, Franz-Werner; … - In: Health Economics Review 4 (2014) 31, pp. 1-14
Early benefit assessment in Germany under the legislative framework of AMNOG (Arzneimittelmarktneuordnungsgesetz … assess the additional benefit of the new drug. However, the Institute for Quality and Efficiency in Health Care (IQWiG …
Persistent link: https://www.econbiz.de/10011599783
Cover Image
Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: Whenever IQWiG and Federal Joint Committee dis...
Dintsios, C. M.; Worm, F.; Ruof, Jörg; Herpers, M. - In: Health Economics Review 9 (2019) 35, pp. 1-15
(FJC) to the HTA body (IQWiG) and their agreement with FJC decisions and to identify potential additional decisive factors … to descriptive statistics, differences between IQWiG and FJC were tested and explored by agreement statistics (Cohen … of the appropriate comparative therapy had a high influence on FJC's appraisals deviating from IQWiG's addenda …
Persistent link: https://www.econbiz.de/10014489869
Cover Image
Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland
Lebioda, Andrea; Gasche, David; Dippel, Franz-Werner; … - In: Health economics review 4 (2014) 31, pp. 1-14
Early benefit assessment in Germany under the legislative framework of AMNOG (Arzneimittelmarktneuordnungsgesetz … assess the additional benefit of the new drug. However, the Institute for Quality and Efficiency in Health Care (IQWiG …
Persistent link: https://www.econbiz.de/10010526947
Cover Image
Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany : whenever IQWiG and Federal Joint Committee di...
Dintsios, C. M.; Worm, F.; Ruof, Jörg; Herpers, M. - In: Health economics review 9 (2019) 35, pp. 1-15
(FJC) to the HTA body (IQWiG) and their agreement with FJC decisions and to identify potential additional decisive factors … to descriptive statistics, differences between IQWiG and FJC were tested and explored by agreement statistics (Cohen … of the appropriate comparative therapy had a high influence on FJC’s appraisals deviating from IQWiG’s addenda …
Persistent link: https://www.econbiz.de/10012162522
Cover Image
Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland
Lebioda, Andrea; Gasche, David; Dippel, Franz-Werner; … - In: Health Economics Review 4 (2014) 1, pp. 1-14
Early benefit assessment in Germany under the legislative framework of AMNOG (Arzneimittelmarktneuordnungsgesetz … assess the additional benefit of the new drug. However, the Institute for Quality and Efficiency in Health Care (IQWiG …
Persistent link: https://www.econbiz.de/10011151927
Cover Image
How can a joint European health technology assessment provide an "additional benefit" over the current standard of national assessments?
Julian, Elaine; Gianfrate, Fabrizio; de Sola-Morales, Oriol - In: Health Economics Review 12 (2022) 1, pp. 1-12
Objectives: We conducted a multi-stakeholder survey to determine key areas where a joint European health technology assessment (HTA) could provide "additional benefit" compared to the status quo of many parallel independent national and subnational assessments. Methods: Leveraging three...
Persistent link: https://www.econbiz.de/10014489870
Cover Image
Shaping a research agenda to ensure a successful European health technology assessment: Insights generated during the inaugural convention of the European Access Academy
Julian, Elaine; Pavlovic, Mira; de Sola-Morales, Oriol; … - In: Health Economics Review 12 (2022) 1, pp. 1-15
Objectives: Key challenges for a joint European Health Technology Assessment (HTA) include consolidated approaches towards the choice of adequate comparator(s), selection of endpoints that are relevant to patients with a given disease, dealing with remaining uncertainties as well as transparent...
Persistent link: https://www.econbiz.de/10014489950